[1]楊月琴,葉中綠.兒童急性淋巴細胞白血病早期治療反應對預后價值的研究[J].醫學信息,2020,(04):51-54.[doi:10.3969/j.issn.1006-1959.2020.04.016]
 YANG Yue-qin,YE Zhong-lv.Study on Early Prognostic Value of Childhood Acute Lymphoblastic Leukemia in Response to Treatment[J].Medical Information,2020,(04):51-54.[doi:10.3969/j.issn.1006-1959.2020.04.016]
點擊復制

兒童急性淋巴細胞白血病早期治療反應對預后價值的研究()
分享到:

醫學信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期數:
2020年04期
頁碼:
51-54
欄目:
綜述
出版日期:
2020-02-15

文章信息/Info

Title:
Study on Early Prognostic Value of Childhood Acute Lymphoblastic Leukemia in Response to Treatment
文章編號:
1006-1959(2020)04-0051-04
作者:
楊月琴葉中綠
(1.廣東醫科大學研究生學院,廣東 湛江 524001;2.廣東醫科大學附屬醫院兒童醫學中心,廣東 湛江 524001)
Author(s):
YANG Yue-qinYE Zhong-lv
(1.Graduate School of Guangdong Medical University,Zhanjiang 524001,Guangdong,China;2.Children’s Medical Center,the Affiliated Hospital of Guangdong Medical University,Zhanjiang 524001,Guangdong,China)
關鍵詞:
急性淋巴細胞白血病誘導化療治療反應預后價值
Keywords:
Acute lymphoblastic leukemiaInduction chemotherapyTreatment responsePrognostic value
分類號:
R733.71
DOI:
10.3969/j.issn.1006-1959.2020.04.016
文獻標志碼:
A
摘要:
兒童急性淋巴細胞白血。ˋLL)是一組高度異質性的惡性血液病,具有發病急、病死率高的特點。采用以分層治療為指導、化療藥物不斷優化組合的治療策略,使兒童ALL患者的預后得到很大改善。早期治療反應是分層治療的重要指標, D8潑尼松敏感試驗、D15骨髓緩解狀態、D33骨髓緩解狀態和D33微小殘留病的早期治療反應是ALL患兒一個獨立預后因素,且ALL患兒誘導化療后的外周血細胞計數也作為早期治療反應指標受到臨床廣泛關注。本文從以上早期治療反應對兒童ALL患者預后的影響作一綜述。
Abstract:
Acute lymphoblastic leukemia (ALL) in children is a group of highly heterogeneous malignant hematological diseases with characteristics of acute onset and high mortality. Adopting stratified therapy as the guide and continuously optimizing the combination of chemotherapeutic drugs, the prognosis of children with ALL has been greatly improved. Early treatment response is an important indicator of stratified treatment. D8 prednisone sensitivity test, D15 bone marrow remission status, D33 bone marrow remission status, and early treatment response of D33 minimal residual disease are independent prognostic factors in children with ALL and peripheral blood cell counts after induction chemotherapy in children with ALL have also received widespread clinical attention as indicators of early treatment response. This article summarizes the impact of the above early treatment responses on the prognosis of children with ALL.

參考文獻/References:

[1]Kato M,Manabe A.Treatment and biology of pediatric acute lymphoblastic leukemia[J].Pediatrics International,2018,60(1):4-12. [2]Pieters R,de Groot-Kruseman H,van der Velden V,et al.Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring:Study ALL10 From the Dutch Childhood Oncology Group[J].Journal of Clinical Oncology,2016,34(22):2591-2601. [3]Stary J,Zimmermann M,Campbell M,et al.Intensive Chemotherapy for Childhood Acute Lymphoblastic Leukemia:Results of the Randomized Intercontinental Trial ALL IC-BFM 2002[J].Journal of Clinical Oncology,2014,32(3):174-184. [4]中國抗癌協會淋巴瘤專業委員會,中國淋巴瘤南方協作組,中國臨床腫瘤學會抗淋巴瘤聯盟.長春堿類藥物治療惡性淋巴瘤中國專家共識[J].中國腫瘤臨床,2017,44(5):193-198. [5]崔蕾,張瑞東,高超,等.兒童急性淋巴細胞白血病早期治療反應評估與預后價值[J].中國實驗血液學雜志,2014,22(2):298-303. [6]高敬.潑尼松誘導試驗與兒童急性淋巴細胞白血病預后關系的Meta分析[D].西南醫科大學,2018. [7]Moricke A,Zimmermann M,Reiter A,et al.Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000[J].Leukemia,2010,24(2):265-284. [8]任媛媛,鄒堯,常麗賢,等.潑尼松反應在CCLG-ALL 2008方案中預后價值的探討[J].中國實驗血液學雜志,2015,23(3):642-646. [9]鄭瑜,蔡云望,符啟昌,等.急性淋巴細胞白血病患兒早期治療反應與預后關系[J].中國實驗血液學雜志,2018,26(3):733-737. [10]Lauten M,Moricke A,Beier R,et al.Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial:differential effects in precursor B-cell and T-cell leukemia[J].Haematologica,2012,97(7):1048-1056. [11]Koka A,Saygin C,Uzunaslan D,et al.A 17-year experience with ALL-BFM protocol in acute lymphoblastic leukemia:Prognostic predictors and interruptions during protocol[J].Leukemia Research,2014,38(6):699-705. [12]Salzer WL,Devidas M,Carroll WL,et al.Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984–2001:a report from the children’s oncology group[J].Leukemia,2010,24(2):355-370. [13]Laughton SJ,Ashton LJ,Kwan E,et al.Early Responses to Chemotherapy of Normal and Malignant Hematologic Cells Are Prognostic in Children With Acute Lymphoblastic Leukemia[J].Journal of Clinical Oncology,2005,23(10):2264-2271. [14]Conter V,Bartram CR,Valsecchi MG,et al.Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia:results in 3184 patients of the AIEOP-BFM ALL 2000 study[J].Blood,2010,115(16):3206-3214. [15]Farkas T,Müller J,Erdelyi DJ,et al.Absolute Lymphocyte Count(ALC)after Induction Treatment Predicts Survival of Pediatric Patients with Acute Lymphoblastic Leukemia[J].Pathology&Oncology Research,2017,23(4):889-897. [16]徐瑞琴,陸小云,張敏.急性白血病緩解期微小殘留病灶與預后的關系[J].臨床血液學雜志,2016,29(2):209-212. [17]Schrappe M,Valsecchi MG,Bartram CR,et al.Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL:results of the AIEOP-BFM-ALL 2000 study[J].Blood,2011,118(8):2077-2084. [18]Borowitz MJ,Devidas M,Hunger SP,et al.Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors:a Children’s Oncology Group study[J].Blood,2008,111(12):5477-5485. [19]Feng J,Feng J Wang Z,et al.Prognostic significance of absolute lymphocyte count at diagnosis of diffuse large B-cell lymphoma:a meta-analysis[J].International Journal of Hematology,2012,95(2):143-148. [20]Rabin KR,Gramatges MM,Borowitz MJ,et al.Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia[J].Pediatric Blood&Cancer,2012,59(3):468-474. [21]Hirase S,Hasegawa D,Takahashi H,et al.Absolute lymphocyte count at the end of induction therapy is a prognostic factor in childhood acute lymphoblastic leukemia[J].International Journal of Hematology,2015,102(5):594-601. [22]Gupta A,Kapoor G,Jain S,et al.Absolute Lymphocyte Count Recovery Independently Predicts Outcome in Childhood Acute Lymphoblastic Leukemia:Experience From a Tertiary Care Cancer Center of a Developing Country[J].J Pediatr Hematol Oncol,2015,37(3):e143-e149. [23]黎巧茹,柯志勇,譚惠珍,等.兒童急性淋巴細胞白血病誘導治療結束時外周血淋巴細胞數與預后的關系[J].熱帶醫學雜志,2016,16(10):1267-1271. [24]Rolf N,Rolf N,Smolen KK,et al.Absolute lymphocyte counts at end of induction correlate with distinct immune cell compartments in pediatric B cell precursor acute lymphoblastic leukemia[J].Cancer Immunology,2018,67(2):225-236. [25]Cheng Y,Luo Z,Yang S,et al.The ratio of absolute lymphocyte count at interim of therapy to absolute lymphocyte count at diagnosis predicts survival in childhood B-lineage acute lymphoblastic leukemia[J].Leukemia Research,2014,39(2):144-150. [26]Zeidler L,Zimmermann M,Moricke A,et al.Low platelet counts after induction therapy for childhood acute lymphoblastic leukemia are strongly associated with poor early response to treatment as measured by minimal residual disease and are prognostic for treatment outcome[J].Haematologica,2012,97(3):402-409. [27]De Angulo G,Yuen C,Palla SL,et al.Absolute lymphocyte count is a novel prognostic indicator in ALL and AML[J].Cancer,2008,112(2):407-415. [28]Long Y,Wang T,Gao Q,et al.Prognostic significance of pretreatment elevated platelet count in patients with colorectal cancer:a meta-analysis[J].Oncotarget,2016,7(49):81849. [29]Lee CH,Lin YJ,Lin CC,et al.Pretreatment platelet count early predicts extrahepatic metastasis of human hepatoma[J].Liver International,2015,35(10):2327-2336. [30]Kopp HG,Placke T,Salih HR.Platelet-Derived Transforming Growth Factor-Down-Regulates NKG2D Thereby Inhibiting Natural Killer Cell Antitumor Reactivity[J].Cancer Research,2009,69(19):7775-7783. [31]黃喆,劉文君,曹汴川,等.兒童急性淋巴細胞白血病血小板參數及血小板膜糖蛋白臨床意義研究[J].中國實用兒科雜志,2017,32(5):366-370. [32]Sharma D,Brummel-Ziedins KE,Bouchard BA,et al.Platelets in Tumor Progression:A Host Factor That Offers Multiple Potential Targets in the Treatment of Cancer[J].Journal of Cellular Physiology,2014,229(8):1005-1015. [33]張傲利,陳曉娟,鄒堯,等.不同血小板水平兒童急性淋巴細胞白血病的臨床特征及預后研究[J].中國當代兒科雜志,2019,21(8):766-771. [34]Faderl S,Thall PF,Kantarjian HM,et al.Time to platelet recovery predicts outcome of patients with de novo acute lymphoblastic leukaemia who have achieved a complete remission[J].British Journal of Haematology,2002,117(4):869-874. [35]Grunnan JD,Rosth?j S.Time course of peripheral blood count recovery during induction chemotherapy for childhood acute lymphoblastic leukemia[J].Hematology,2019,24(1):467-472.

相似文獻/References:

[1]黃倩云,李長鋼.門冬酰胺酶對白血病患兒靜脈血栓形成的研究進展[J].醫學信息,2018,(12):39.[doi:10.3969/j.issn.1006-1959.2018.12.013]
 HUANG Qian-yun,LI Chang-gang.Advances in the Treatment of Venous Thrombosis in Children with Leukemia by Asparaginase[J].Medical Information,2018,(04):39.[doi:10.3969/j.issn.1006-1959.2018.12.013]
[2]韓怡波.兒童急淋大劑量甲氨蝶呤延遲解救的安全性研究[J].醫學信息,2019,(19):143.[doi:10.3969/j.issn.1006-1959.2019.19.046]
 HAN Yi-bo.Safety Study on Delayed Rescue of High-Dose Methotrexate in Children[J].Medical Information,2019,(04):143.[doi:10.3969/j.issn.1006-1959.2019.19.046]

更新日期/Last Update: 2020-02-15
中国足彩网竞彩 短线股票贴吧 河内五分彩app 快乐扑克 江西11选五胆拖表 快乐十分开奖结果云南体彩 股票指数有什么作用 翼支付 极速赛车大小单双稳赚 pk10滚雪球计划选号 2017赛车pk10官网直播 广西双彩24选7的走势图